Skip to main content
Journal cover image

Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).

Publication ,  Journal Article
Storey, RF; Becker, RC; Harrington, RA; Husted, S; James, SK; Cools, F; Steg, PG; Khurmi, NS; Emanuelsson, H; Lim, ST; Cannon, CP; Katus, HA ...
Published in: The American journal of cardiology
December 2011

The Platelet Inhibition and Patient Outcomes (PLATO) trial showed that ticagrelor reduced the risk for cardiovascular events in patients with acute coronary syndromes compared to clopidogrel but was associated with increased incidence of dyspnea. This substudy assessed whether ticagrelor affects pulmonary function in patients with acute coronary syndromes: 199 patients enrolled in the PLATO trial and receiving randomized treatment with ticagrelor 90 mg twice daily (n = 101) or clopidogrel 75 mg/day (n = 98) took part in the pulmonary function substudy. Patients with advanced lung disease, congestive heart failure, or coronary artery bypass graft surgery after the index event were excluded. Pulse oximetry (blood oxygen saturation), spirometry (forced expiratory volume in 1 second, forced vital capacity, and forced expiratory flow between 25% and 75% of forced vital capacity before and 20 minutes after inhalation of a β(2) agonist), lung volumes (total lung capacity, functional residual capacity, residual volume), and diffusion capacity were performed after patients received study medication for 30 to 40 days. Tests were then repeated <10 days before and approximately 30 days after the discontinuation of study medication. After a mean treatment duration of 31 days, there were no differences between the groups for any of the pulmonary function parameters. At the end of treatment (mean 211 days) and after the discontinuation of study medication (mean 32 days after the last dose), there was also no evidence of a change in pulmonary function in either group. For example, forced expiratory volume in 1 second values before β(2) agonist inhalation in the ticagrelor and clopidogrel groups were 2.81 ± 0.73 and 2.70 ± 0.84 L, respectively, at the first visit and did not change significantly at subsequent visits. In conclusion, no effect of ticagrelor on pulmonary function was seen in this cohort of patients with acute coronary syndromes compared to clopidogrel.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

The American journal of cardiology

DOI

EISSN

1879-1913

ISSN

0002-9149

Publication Date

December 2011

Volume

108

Issue

11

Start / End Page

1542 / 1546

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Ticlopidine
  • Ticagrelor
  • Respiratory Function Tests
  • Purinergic P2Y Receptor Antagonists
  • Prospective Studies
  • Platelet Aggregation Inhibitors
  • Oxygen Consumption
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Storey, R. F., Becker, R. C., Harrington, R. A., Husted, S., James, S. K., Cools, F., … Wallentin, L. (2011). Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). The American Journal of Cardiology, 108(11), 1542–1546. https://doi.org/10.1016/j.amjcard.2011.07.015
Storey, Robert F., Richard C. Becker, Robert A. Harrington, Steen Husted, Stefan K. James, Frank Cools, Philippe Gabriel Steg, et al. “Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).The American Journal of Cardiology 108, no. 11 (December 2011): 1542–46. https://doi.org/10.1016/j.amjcard.2011.07.015.
Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F, et al. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). The American journal of cardiology. 2011 Dec;108(11):1542–6.
Storey, Robert F., et al. “Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).The American Journal of Cardiology, vol. 108, no. 11, Dec. 2011, pp. 1542–46. Epmc, doi:10.1016/j.amjcard.2011.07.015.
Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F, Steg PG, Khurmi NS, Emanuelsson H, Lim ST, Cannon CP, Katus HA, Wallentin L. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). The American journal of cardiology. 2011 Dec;108(11):1542–1546.
Journal cover image

Published In

The American journal of cardiology

DOI

EISSN

1879-1913

ISSN

0002-9149

Publication Date

December 2011

Volume

108

Issue

11

Start / End Page

1542 / 1546

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Ticlopidine
  • Ticagrelor
  • Respiratory Function Tests
  • Purinergic P2Y Receptor Antagonists
  • Prospective Studies
  • Platelet Aggregation Inhibitors
  • Oxygen Consumption
  • Middle Aged